期刊文献+

抗体技术研究进展(2):小分子抗体及功能复合化抗体 被引量:1

Recent advances in antibody technique 2. Antibodies of small-molecule and composite function
下载PDF
导出
摘要 随着分子生物学的发展,基因工程小分子抗体以及纳米抗体由于其分子质量小、结构简单、异源性低、组织穿透能力强及易于大量生产等优点而越来越受到人们的关注,并且其与毒素、酶、细胞因子等生物活性物质融合可产生功能复合化抗体——抗体融合蛋白,在肿瘤的诊断和治疗中具有广阔的应用前景.本研究主要就小分子抗体、功能复合化抗体以及纳米抗体近几年的发展与应用进行综述. With the development of molecular biology, gene-engineering small-molecular antibodies and nanobodies have become more and more important for their properties of small molecular weight, sim- ple structure, low immunogenicity, rapid penetration and economical produce and so on. These antibod- ies, which can be linked or fused to a vast range of molecules such as toxins, enzymes, cytokines, etc, have a great future in tumors diagnose and therapy. This review gives an overview on the development of antibodies of small-molecular and composite function and nanobodies in recent years.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2013年第5期556-563,共8页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 国家自然基金项目(81202449) 广东省科技计划项目(201213010300016)
关键词 小分子抗体 抗体融合蛋白 功能复合化抗体 纳米抗体 small-molecule antibody antibody fusion protein nanobodycomposite function antibody
  • 相关文献

参考文献31

  • 1VERGARA-JIMENEZ J, TRICOCI P. Safety and efficacy of abciximab as an adjunct to percutaneous coronary inter- vention [ J ]. Vasc Health Risk Manag, 2010,6 ( 3 ) : 39 - 45.
  • 2KANG S, ROH Y J. Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration[ J ]. Jpn J Ophthalmol,2011,55 (2) : 123 - 127.
  • 3GOEL N, STEPHENS S. Certolizumab pegol [ J ]. MAbs, 2010,2(2) :137 - 147.
  • 4XIANGJUN-Jian,TONGJi-yu,WANGHong.抗体技术研究进展(1):人源抗体技术[J].暨南大学学报:自然科学版,2012,33(5):524-530.
  • 5GIBSON C M, PRIDE Y B. Myocardial infarct size reduc- tion with pexelizumab: The role of chance is patently clear[ J ]. JACC Cardiovasc Imaging, 2010,3 ( 1 ) : 61 - 63.
  • 6HOLLIGER P, PROSPERO T, WINTER G, "Diabodies" : small bivalent and bispecific antibody fragments [ J ]. Proc Natl Acad Sci U S A,1993,90(14) :6A.A.A. -6448.
  • 7LUM L G, DAVOL P A, LEE R J. The new face of bispe- cific antibodies: targeting cancer and much more [ J ]. Exp Hemato1,2006, 34( 1 ) : 1 - 6.
  • 8FISCHER N, LEGER O. Bispecific antibodies: Mole- cules that enable novel therapeutic strategies [ J ]. Patho- biology,2007,74( 1 ) :3 - 14.
  • 9MARKUS M,PATRICK A B, OLIVIER G. The emerging role of EpCAM in cancer and stem cell signaling [ J ]. Cancer Research,2009,69 (14) :5627 - 5629.
  • 10MICHAEL J, ALEXANDRA S, PETER R, et al. The tri- functional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor re- ceptor 2 [ J ]. Cancer Research, 2009,69 ( 10 ) : 4270 - 4276.

二级参考文献9

共引文献11

同被引文献13

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部